drugset / Trial / NCT04369534
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
Phase 4
Completed
120 enrolled
University of Zagreb
Clinical Hospital Centre Zagreb · collabCroatian Science Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The specific goal of this study is to determine whether the individualized approach and adjusting the dosage of the P2Y12 receptor inhibitors will improve the platelet inhibiton and the clinical outcome in patients with an ACS, that were treated with PCI and the aforementioned drugs, but with an increased initial residual platelet activity. It is expected that the patients that have undergone the P2Y12 inhibitor therapy adjustment (according to the platelet reactivity measured by POC devices) will have better clinical outcomes (ie less ischemic events, without a significant increase in bleeding events) than those who did not undergo the therapy adjustment.
Timeline
- Start
- 2015-12-01
- Primary completion
- 2019-11-30
- Completion
- 2019-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | — | — |
| Comparator | Ticagrelor | Small molecule | — | — |